Capasso Planning Partners LLC Sells 4,917 Shares of Johnson & Johnson (NYSE:JNJ)

Capasso Planning Partners LLC lessened its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 54.3% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,138 shares of the company's stock after selling 4,917 shares during the period. Capasso Planning Partners LLC's holdings in Johnson & Johnson were worth $671,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of JNJ. Inspire Trust Co. N.A. grew its holdings in shares of Johnson & Johnson by 12.2% during the 3rd quarter. Inspire Trust Co. N.A. now owns 24,063 shares of the company's stock worth $3,900,000 after acquiring an additional 2,610 shares during the period. Old North State Trust LLC raised its holdings in Johnson & Johnson by 1.6% in the third quarter. Old North State Trust LLC now owns 7,553 shares of the company's stock worth $1,224,000 after purchasing an additional 120 shares in the last quarter. Franklin Resources Inc. lifted its position in Johnson & Johnson by 11.4% during the third quarter. Franklin Resources Inc. now owns 16,840,069 shares of the company's stock valued at $2,721,355,000 after buying an additional 1,729,281 shares during the period. Tidal Investments LLC grew its position in shares of Johnson & Johnson by 11.1% in the 3rd quarter. Tidal Investments LLC now owns 186,860 shares of the company's stock worth $30,283,000 after buying an additional 18,605 shares during the period. Finally, Destination Wealth Management increased its stake in shares of Johnson & Johnson by 2.7% in the 3rd quarter. Destination Wealth Management now owns 268,537 shares of the company's stock worth $43,519,000 after acquiring an additional 7,133 shares in the last quarter. Institutional investors own 69.55% of the company's stock.

Insider Activity

In related news, Director Mark A. Weinberger purchased 1,000 shares of the business's stock in a transaction on Thursday, December 12th. The stock was acquired at an average price of $147.22 per share, with a total value of $147,220.00. Following the completion of the acquisition, the director now owns 1,000 shares of the company's stock, valued at approximately $147,220. This trade represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 0.16% of the company's stock.

Johnson & Johnson Stock Performance

Shares of JNJ traded up $0.36 during mid-day trading on Friday, hitting $146.60. 8,323,370 shares of the company traded hands, compared to its average volume of 7,123,697. The stock has a market cap of $352.96 billion, a price-to-earnings ratio of 21.16, a P/E/G ratio of 2.52 and a beta of 0.51. The stock has a 50-day moving average price of $157.01 and a two-hundred day moving average price of $156.28. Johnson & Johnson has a 1 year low of $143.13 and a 1 year high of $168.85. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share for the quarter, beating analysts' consensus estimates of $2.21 by $0.21. The business had revenue of $22.47 billion during the quarter, compared to analyst estimates of $22.17 billion. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The company's quarterly revenue was up 5.2% compared to the same quarter last year. During the same period in the previous year, the business earned $2.66 EPS. Equities analysts anticipate that Johnson & Johnson will post 9.94 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th were paid a dividend of $1.24 per share. The ex-dividend date of this dividend was Tuesday, November 26th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.38%. Johnson & Johnson's dividend payout ratio is currently 71.78%.

Wall Street Analysts Forecast Growth

JNJ has been the topic of a number of recent research reports. Citigroup cut their price objective on shares of Johnson & Johnson from $185.00 to $175.00 and set a "buy" rating on the stock in a report on Wednesday. Cantor Fitzgerald restated an "overweight" rating and issued a $215.00 price target on shares of Johnson & Johnson in a research note on Wednesday, October 16th. Wolfe Research initiated coverage on Johnson & Johnson in a research note on Friday, November 15th. They set an "outperform" rating and a $190.00 price objective for the company. Bank of America reissued a "neutral" rating and issued a $166.00 target price on shares of Johnson & Johnson in a research note on Tuesday. Finally, Guggenheim lifted their price target on Johnson & Johnson from $156.00 to $162.00 and gave the stock a "neutral" rating in a research report on Wednesday, November 6th. Seven analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $174.73.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.